Fulcrum Therapeutics’ (FULC) “Underweight” Rating Reaffirmed at JPMorgan Chase & Co.

JPMorgan Chase & Co. reiterated their underweight rating on shares of Fulcrum Therapeutics (NASDAQ:FULC) in a report issued on Wednesday morning, MarketBeat.com reports.

Other analysts have also issued research reports about the company. Cantor Fitzgerald lowered Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Stifel Nicolaus lowered Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $3.00 price objective on the stock. in a research note on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Tuesday, April 21st. Truist Financial lowered Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $4.00 price objective on the stock. in a research note on Tuesday. Finally, Wall Street Zen upgraded Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 2nd. One analyst has rated the stock with a Buy rating, seven have given a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce” and an average target price of $8.20.

Fulcrum Therapeutics Stock Performance

Shares of NASDAQ FULC opened at $3.22 on Wednesday. The stock has a 50 day moving average price of $7.08 and a 200 day moving average price of $9.14. Fulcrum Therapeutics has a 52 week low of $2.83 and a 52 week high of $15.74. The stock has a market capitalization of $214.55 million, a PE ratio of -2.80 and a beta of 2.93.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings data on Monday, April 27th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.06. As a group, research analysts forecast that Fulcrum Therapeutics will post -1.16 EPS for the current year.

Hedge Funds Weigh In On Fulcrum Therapeutics

A number of large investors have recently made changes to their positions in FULC. Cubist Systematic Strategies LLC bought a new position in shares of Fulcrum Therapeutics during the first quarter worth approximately $164,000. Jane Street Group LLC increased its stake in shares of Fulcrum Therapeutics by 62.1% during the first quarter. Jane Street Group LLC now owns 117,816 shares of the company’s stock worth $339,000 after purchasing an additional 45,157 shares during the period. Creative Planning bought a new position in shares of Fulcrum Therapeutics during the second quarter worth approximately $117,000. Legal & General Group Plc increased its stake in shares of Fulcrum Therapeutics by 230.2% during the second quarter. Legal & General Group Plc now owns 17,461 shares of the company’s stock worth $120,000 after purchasing an additional 12,173 shares during the period. Finally, American Century Companies Inc. increased its stake in shares of Fulcrum Therapeutics by 7.0% during the second quarter. American Century Companies Inc. now owns 132,349 shares of the company’s stock worth $911,000 after purchasing an additional 8,638 shares during the period. Institutional investors own 89.83% of the company’s stock.

More Fulcrum Therapeutics News

Here are the key news stories impacting Fulcrum Therapeutics this week:

• Negative Sentiment: Fulcrum discontinued pociredir after FDA safety concerns, effectively removing its only clinical-stage asset and sharply weakening the company’s near-term outlook. Reuters article
• Negative Sentiment: Multiple brokerages downgraded the stock, including Cantor Fitzgerald, Leerink Partners, Stifel, HC Wainwright, and JPMorgan, reflecting reduced confidence after the program shutdown.
• Negative Sentiment: Several law firms and shareholder groups announced investigations into possible securities-law violations, adding litigation risk and more uncertainty for investors. PR Newswire article
• Neutral Sentiment: The company is exploring strategic alternatives, including a potential sale or merger, which could provide a catalyst if value can be salvaged from the remaining assets. Yahoo Finance article

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.